• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用氧乐酶克服药物降解挑战对非结核分枝杆菌进行奥马环素药物敏感性测试。

Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.

机构信息

Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, TX, USA.

Mathematical Modeling and AI Department, Praedicare Inc., Dallas, TX, USA; Hollow Fiber System & Experimental Therapeutics Laboratories, Wet Lab Systems, Praedicare Inc., Dallas, TX, USA.

出版信息

Tuberculosis (Edinb). 2024 Jul;147:102519. doi: 10.1016/j.tube.2024.102519. Epub 2024 May 13.

DOI:10.1016/j.tube.2024.102519
PMID:38754247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11345947/
Abstract

BACKGROUND

Drug susceptibility testing (DST) protocol of omadacycline against non-tuberculous mycobacteria has not yet been established. We developed a method to accurately determine MIC omadacycline MIC against Mycobacterium abscessus (Mab), Mycobacterium avium-complex (MAC), and Mycobacterium kansasii (Mkn).

METHODS

First, we identified the oxyrase concentration not affecting Mab, MAC, and Mkn growth followed by omadacycline MIC experiments with and without oxyrase using reference and clinical strains.

RESULTS

Oxyrase 0.5 % (v/v) stabilized omadacycline in the culture medium. The median omadacycline MIC was 1 mg/L for Mab and 8 mg/L for Mkn. For MAC, the median omadacycline MIC was 2 mg/L for M. avium, 256 mg/L for M. intracellulare, and 4 mg/L for M. chimaera (p < 0.0001). Wilcoxon matched-pairs signed rank test revealed statistically lower MICs with oxyrase for all MAC subspecies (p < 0.0001), all Mab subspecies (p < 0.0001), and Mkn (p = 0.0002). The decrease in MICs with oxyrase was 17/18 of Mab, 14/19 of Mkn, 8/8 of M. avium, 4/5 M. chimera, but only 11/18 of M. intracellulare (p < 0.013).

CONCLUSION

Use of 0.5 % oxyrase could be a potential solution to reliable and reproducible omadacycline MIC of Mab. However, oxyrase demonstrated a variable effect in reducing MICs against MAC and Mkn.

摘要

背景

目前尚未建立美满霉素(omadacycline)对非结核分枝杆菌的药敏试验(DST)方案。我们开发了一种方法,可准确测定脓肿分枝杆菌(Mab)、鸟分枝杆菌复合群(MAC)和堪萨斯分枝杆菌(Mkn)对美满霉素的 MIC 值。

方法

首先,我们确定了不会影响 Mab、MAC 和 Mkn 生长的氧化酶浓度,然后使用参考菌株和临床分离株进行了有和无氧化酶的美满霉素 MIC 实验。

结果

氧化酶 0.5%(v/v)稳定了培养基中的美满霉素。Mab 的美满霉素 MIC 中位数为 1mg/L,Mkn 为 8mg/L。对于 MAC,鸟分枝杆菌、胞内分枝杆菌和偶发分枝杆菌的美满霉素 MIC 中位数分别为 2mg/L、256mg/L 和 4mg/L(p<0.0001)。Wilcoxon 配对符号秩检验显示,所有 MAC 亚种(p<0.0001)、所有 Mab 亚种(p<0.0001)和 Mkn(p=0.0002)的 MIC 值均随氧化酶的使用而降低。氧化酶降低 MIC 值的情况为:18 株 Mab 中有 17 株、19 株 Mkn 中有 14 株、8 株鸟分枝杆菌中有 8 株、5 株偶发分枝杆菌中有 4 株,而胞内分枝杆菌只有 18 株中有 11 株(p<0.013)。

结论

使用 0.5%氧化酶可能是可靠且重现性地测定 Mab 美满霉素 MIC 的一种潜在方法。然而,氧化酶在降低 MAC 和 Mkn 的 MIC 值方面表现出可变的效果。

相似文献

1
Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.利用氧乐酶克服药物降解挑战对非结核分枝杆菌进行奥马环素药物敏感性测试。
Tuberculosis (Edinb). 2024 Jul;147:102519. doi: 10.1016/j.tube.2024.102519. Epub 2024 May 13.
2
The activity of carbapenems alone and in combination with β-lactamase inhibitors against difficult-to-treat mycobacteria; and complex: A systematic review.碳青霉烯类单独及与β-内酰胺酶抑制剂联合应用对难治疗分枝杆菌及复合体的活性:一项系统评价
Int J Mycobacteriol. 2023 Jul-Sep;12(3):211-225. doi: 10.4103/ijmy.ijmy_131_23.
3
Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.贝达喹啉和德拉马尼对非结核分枝杆菌(包括大环内酯类耐药临床分离株)的活性。
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00665-19. Print 2019 Aug.
4
Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.迈向非结核分枝杆菌临床折点 - 使用肉汤微量稀释法测定鸟分枝杆菌复合群和脓肿分枝杆菌的流行病学切点值。
Clin Microbiol Infect. 2023 Jun;29(6):758-764. doi: 10.1016/j.cmi.2023.02.007. Epub 2023 Feb 20.
5
Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria.检测奥马环素对非结核分枝杆菌的药敏试验所面临的挑战及潜在解决方案。
Tuberculosis (Edinb). 2022 Dec;137:102269. doi: 10.1016/j.tube.2022.102269. Epub 2022 Oct 4.
6
Microbiological and Clinical Outcomes of Treating Non-Mycobacterium Avium Complex Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta-Analysis.治疗非结核分枝杆菌肺病的微生物学和临床结局:系统评价和荟萃分析。
Chest. 2017 Jul;152(1):120-142. doi: 10.1016/j.chest.2017.04.166. Epub 2017 Apr 28.
7
Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria.奥马环素对非结核分枝杆菌的药敏试验。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01947-20.
8
Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan.台湾地区伴侣动物中分离出的快速生长分枝杆菌的抗菌耐药性。
Microbiol Spectr. 2025 Jul;13(7):e0307424. doi: 10.1128/spectrum.03074-24. Epub 2025 May 19.
9
Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.囊性纤维化患者非结核分枝杆菌肺部感染的抗生素治疗
Cochrane Database Syst Rev. 2016 Dec 19;12(12):CD010004. doi: 10.1002/14651858.CD010004.pub4.
10
Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria.替加环素、依拉环素、奥马环素和沙雷环素对快速生长分枝杆菌的抗菌活性。
Microbiol Spectr. 2023 Feb 14;11(1):e0323822. doi: 10.1128/spectrum.03238-22. Epub 2022 Dec 8.

引用本文的文献

1
Repurposing drugs to advance the treatment of Buruli ulcer.重新利用药物以推进布鲁里溃疡的治疗。
Antimicrob Agents Chemother. 2025 May 7;69(5):e0002925. doi: 10.1128/aac.00029-25. Epub 2025 Mar 26.
2
Comparative efficacy of tetracyclines against isolates of complex.四环素对复合体分离株的比较疗效。
IJTLD Open. 2025 Feb 1;2(2):113-115. doi: 10.5588/ijtldopen.24.0551. eCollection 2025 Feb.
3
Development of tetracycline analogues with increased aqueous stability for the treatment of mycobacterial infections.开发具有更高水稳定性的四环素类似物用于治疗分枝杆菌感染。
Tuberculosis (Edinb). 2025 Jan;150:102592. doi: 10.1016/j.tube.2024.102592. Epub 2024 Dec 13.

本文引用的文献

1
Long-term Safety and Tolerability of Omadacycline for the Treatment of Infections.奥马环素治疗感染的长期安全性和耐受性
Open Forum Infect Dis. 2023 Jul 3;10(7):ofad335. doi: 10.1093/ofid/ofad335. eCollection 2023 Jul.
2
Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease.奥马环素在中空纤维模型中的药代动力学/药效学及治疗肺部脓肿分枝杆菌病的疗效临床验证。
Int J Antimicrob Agents. 2023 Jul;62(1):106847. doi: 10.1016/j.ijantimicag.2023.106847. Epub 2023 May 13.
3
Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease.含奥马环素方案在肺部脓肿分枝杆菌病小鼠模型中的疗效。
mSphere. 2023 Apr 20;8(2):e0066522. doi: 10.1128/msphere.00665-22. Epub 2023 Mar 13.
4
Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria.检测奥马环素对非结核分枝杆菌的药敏试验所面临的挑战及潜在解决方案。
Tuberculosis (Edinb). 2022 Dec;137:102269. doi: 10.1016/j.tube.2022.102269. Epub 2022 Oct 4.
5
Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease.奥马环素在中空纤维系统模型中的药代动力学/药效学及其在短程治疗堪萨斯分枝杆菌肺病的潜在联合方案。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0068722. doi: 10.1128/aac.00687-22. Epub 2022 Aug 17.
6
Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses.奥马环素在中空纤维系统模型中治疗肺部鸟分枝杆菌复合群的疗效和临床可达到的剂量下的效力。
J Antimicrob Chemother. 2022 May 29;77(6):1694-1705. doi: 10.1093/jac/dkac068.
7
Omadacycline Potentiates Clarithromycin Activity Against .奥马环素增强克拉霉素对……的活性。 (原文结尾不完整)
Front Pharmacol. 2021 Dec 8;12:790767. doi: 10.3389/fphar.2021.790767. eCollection 2021.
8
Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates and in a Mouse Model of Pulmonary Infection.奥马环素对脓肿分枝杆菌临床分离株的效价及肺部感染小鼠模型的疗效。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0170421. doi: 10.1128/AAC.01704-21. Epub 2021 Oct 18.
9
Preliminary, Real-world, Multicenter Experience With Omadacycline for Infections.奥马环素治疗感染的初步、真实世界、多中心经验
Open Forum Infect Dis. 2021 Jan 7;8(2):ofab002. doi: 10.1093/ofid/ofab002. eCollection 2021 Feb.
10
In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii.体外奥马环素对大肠杆菌和鲍曼不动杆菌的药效学研究。
J Antimicrob Chemother. 2021 Feb 11;76(3):667-670. doi: 10.1093/jac/dkaa508.